Successfully Holds Extraordinary General Meeting of Shareholders, Phapros (PEHA) Appoints Intan Abdams Katoppo as New Captain

JAKARTA, April 28, 2026 – PT Phapros Tbk (PEHA), a leading pharmaceutical company in Indonesia, successfully held an Extraordinary General Meeting of Shareholders (EGMS/RUPS-LB) in Jakarta on Monday, April 27, 2026.

The EGMS approved the reappointment and changes to the composition of both the Board of Commissioners and the Board of Directors. The EGMS agreed to honorably discharge Maxi Rein Rondonuwu as President Commissioner for the 2021-2026 period, Chrisma Aryani Albandjar as Independent Commissioner for the 2021-2026 period, and Yudhi Rangkuti as Director of Finance, Risk Management & HR for the 2023-2026 period.

Furthermore, the EGMS approved the appointment of Alfi N. Rustam as President Commissioner, Nurjayanto Kusumawardhono as Independent Commissioner, Intan Abdams Katoppo as President Director, and Ferdinand Troedu as Director of Finance, Risk Management & HR.

Previously, Production Director Ida Rahmi Kurniasih served concurrently as the Acting President Director of PT Phapros Tbk. Now, Phapros has a permanent President Director entrusted to Intan Abdams Katoppo. As the new captain of PEHA, Intan possesses extensive experience in leading corporations across both private and state-owned enterprises (BUMN).

The following is the management structure of PT Phapros Tbk, in accordance with the 2026 EGMS Decree:

Board of Commissioners:

• President Commissioner: Alfi Novtriansyah Rustam

• Independent Commissioner: Nurjayanto Kusumawardhono

• Independent Commissioner: Bimo Wijayanto

• Commissioner: Masrizal Achmad Syarief

Board of Directors:

• President Director: Intan Abdams Katoppo

• Production Director: Ida Rahmi Kurniasih

• Marketing Director: Maraja Jeson Siregar

• Director of Finance, Risk Management & HR: Ferdinand Troedu

Zahmilia Akbar, GM Corporate Secretary of PT Phapros Tbk, stated that the entire management of PT Phapros Tbk expresses its gratitude to Mr. Maxi Rein Rondonuwu, Mrs. Chrisma Aryani Albandjar, and Mr. Yudhi Rangkuti for their dedication and hard work. Their contributions have allowed Phapros to navigate challenging times over the last five years and successfully demonstrate financial performance growth starting in 2025.

According to her, the changes in the Board of Commissioners and Board of Directors represent an organizational refreshment. It is hoped that the Company can continue the business transformation already underway to achieve sustainable performance growth in the coming years.

"Phapros remains committed to providing the best healthcare products and services to the Indonesian people while simultaneously targeting positive growth as a professional and healthy corporation. Maintaining the trust of all stakeholders is our primary goal," Zahmilia concluded on Monday (28/4/2026).